Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 2

Conditions

Pancreatic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 300Fluorouracil 273Bevacizumab 238Gemcitabine 235Leucovorin 213Capecitabine 207pembrolizumab 202Nivolumab 158Irinotecan 158Cisplatin 150Specimen Handling 144Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 118Paclitaxel 109durvalumab 106Cetuximab 104Radiotherapy 99atezolizumab 94Drug Therapy 94Biopsy 93tislelizumab 81Albumin-Bound Paclitaxel 81Taxes 74Folfox protocol 68lenvatinib 67Carboplatin 66regorafenib 60Blood Specimen Collection 60sintilimab 54Ipilimumab 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
C188-9 compound × Gastrointestinal × 1 year × Clear all
NCT06141031 2026-05-27

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1 Recruiting
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05440708 2026-04-27

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Tvardi Therapeutics, Incorporated

Phase 1/2 Recruiting
193 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡